Page last updated: 2024-09-04

atrasentan and Breast Neoplasms

atrasentan has been researched along with Breast Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fischgräbe, J; Götte, M; Kiesel, L; Michels, K; Wülfing, P	1
Carducci, MA; Jimeno, A	1
Fischgräbe, J; Götte, M; Kersting, C; Kiesel, L; Smollich, M; Wülfing, P	1

Reviews

1 review(s) available for atrasentan and Breast Neoplasms

Article	Year
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-15, Volume: 12, Issue:20 Pt 2 Topics: Antineoplastic Agents; Atrasentan; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Endothelin Receptor Antagonists; Female; Humans; Male; Prostatic Neoplasms; Pyrrolidines	2006

Article

Year

Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-15, Volume: 12, Issue:20 Pt 2

Topics: Antineoplastic Agents; Atrasentan; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Endothelin Receptor Antagonists; Female; Humans; Male; Prostatic Neoplasms; Pyrrolidines

2006

Other Studies

2 other study(ies) available for atrasentan and Breast Neoplasms

Article	Year
Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells. International journal of cancer, 2010, Aug-01, Volume: 127, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrasentan; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Synergism; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Phosphorylation; Pyrrolidines; Receptor, Endothelin A; Trastuzumab	2010
Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion. Breast cancer research and treatment, 2008, Volume: 108, Issue:2 Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Atrasentan; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasm Staging; Pyrrolidines; Receptor, Endothelin A; Time Factors; Up-Regulation	2008

Article

Year

Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.

International journal of cancer, 2010, Aug-01, Volume: 127, Issue:3

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atrasentan; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Synergism; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Female; Genes, erbB-2; Humans; Neoplasm Metastasis; Phosphorylation; Pyrrolidines; Receptor, Endothelin A; Trastuzumab

2010

Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.

Breast cancer research and treatment, 2008, Volume: 108, Issue:2

Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Atrasentan; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cobalt; Endothelin A Receptor Antagonists; Endothelin-1; Endothelin-Converting Enzymes; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Metalloendopeptidases; Neoplasm Invasiveness; Neoplasm Staging; Pyrrolidines; Receptor, Endothelin A; Time Factors; Up-Regulation

2008